KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Non-Current Debt (2020 - 2025)

Regeneron Pharmaceuticals (REGN) has 6 years of Non-Current Debt data on record, last reported at $2.0 billion in Q4 2025.

  • For Q4 2025, Non-Current Debt changed 0.08% year-over-year to $2.0 billion; the TTM value through Dec 2025 reached $2.0 billion, changed 0.08%, while the annual FY2025 figure was $2.0 billion, 0.08% changed from the prior year.
  • Non-Current Debt reached $2.0 billion in Q4 2025 per REGN's latest filing, roughly flat from $2.0 billion in the prior quarter.
  • Across five years, Non-Current Debt topped out at $2.0 billion in Q4 2025 and bottomed at $2.0 billion in Q1 2021.
  • Average Non-Current Debt over 5 years is $2.0 billion, with a median of $2.0 billion recorded in 2023.
  • Peak YoY movement for Non-Current Debt: rose 0.07% in 2021, then grew 0.08% in 2022.
  • A 5-year view of Non-Current Debt shows it stood at $2.0 billion in 2021, then grew by 0.09% to $2.0 billion in 2022, then rose by 0.08% to $2.0 billion in 2023, then grew by 0.08% to $2.0 billion in 2024, then increased by 0.08% to $2.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $2.0 billion in Q4 2025, $2.0 billion in Q3 2025, and $2.0 billion in Q2 2025.